Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 21, 2014; 20(27): 8993-8997
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8993
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8993
De-escalating therapy in gastric aggressive lymphoma
Rosanna Cuccurullo, Silvia Govi, Andrés JM Ferreri, Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
Author contributions: Cuccurullo R, Govi S and Ferreri AJM performed literature revision, critically analyzed reported studies and wrote the manuscript.
Correspondence to: Andrés JM Ferreri, MD, Unit of Lymphoid Malignancies, Division of OncoHematological Medicine, Department of OncoHematology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. ferreri.andres@hsr.it
Telephone: +39-2-26437649 Fax: +39-2-26437625
Received: November 29, 2014
Revised: January 14, 2014
Accepted: March 12, 2014
Published online: July 21, 2014
Revised: January 14, 2014
Accepted: March 12, 2014
Published online: July 21, 2014
Core Tip
Core tip: Therapeutic intensity has been progressively reduced in patients with limited-stage diffuse large B-cell lymphoma of the stomach, with a consequent improvement in tolerability and quality of life, and with unimpaired survival figures. In particular, patients with Helicobacter pylori (H. pylori)-positive lymphoma and favourable prognostic factors can be managed with antibiotics alone, with excellent disease control and cure rates, keeping chemo-radiotherapy for unresponsive patients. Future studies should be focused on the establishment of reliable variables able to distinguish the best candidates for exclusive treatment with H. pylori eradication from those who need for conventional therapy.